Moleculin Biotech (MBRX) Short Interest Ratio & Short Volume → New trading system called MSFT, NVDA & MSFT (From WealthPress) (Ad) Free MBRX Stock Alerts $4.31 -0.01 (-0.23%) (As of 06/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Moleculin Biotech Short Interest DataCurrent Short Interest34,200 sharesPrevious Short Interest31,100 sharesChange Vs. Previous Month+9.97%Dollar Volume Sold Short$168,264.00Short Interest Ratio0.9 Days to CoverLast Record DateMay 15, 2024Outstanding Shares2,310,000 sharesFloat Size2,230,000 sharesShort Percent of Float1.53%Today's Trading Volume6,521 sharesAverage Trading Volume14,886 sharesToday's Volume Vs. Average44% Short Selling Moleculin Biotech ? Sign up to receive the latest short interest report for Moleculin Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMBRX Short Interest Over TimeMBRX Days to Cover Over TimeMBRX Percentage of Float Shorted Over Time Ad DTIDo you know the 3 golden rules for dividend investing? Would you like a simple set of guidelines for building a rock solid dividend portfolio? Including the two specific tickers I just put $50k into? Well, it’s all included in these FIVE Dividend Cheat SheetsYou can grab your FREE, laminated copies right here Moleculin Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202434,200 shares $168,264.00 +10.0%1.5%0.9 $4.92 4/30/202431,100 shares $156,122.00 +16.5%1.5%0.8 $5.02 4/15/202426,700 shares $119,082.00 -40.7%1.2%0.8 $4.46 3/31/202445,000 shares $265,950.00 +2,042.9%2.1%1.4 $5.91 3/15/20242,100 shares $15,576.75 -98.4%0.1%0.1 $7.42 2/29/2024134,400 shares $84,537.60 -2.4%N/A0.8 $0.63 Get the Latest News and Ratings for MBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024137,700 shares $68,850.00 -37.4%N/A0.9 $0.50 1/31/2024220,000 shares $110,880.00 -8.5%N/A1.2 $0.50 1/15/2024240,300 shares $170,613.00 -23.8%N/A1.3 $0.71 12/31/2023315,300 shares $270,653.52 -7.5%N/A1.6 $0.86 12/15/2023340,800 shares $197,664.00 +35.3%N/A2.1 $0.58 11/30/2023251,900 shares $150,812.53 -15.2%N/A1.7 $0.60 11/15/2023296,900 shares $169,233.00 +59.7%N/A1.9 $0.57 10/31/2023185,900 shares $90,012.78 +131.8%N/A1.5 $0.48 10/15/202380,200 shares $36,090.00 -55.3%N/A0.7 $0.45 9/30/2023179,300 shares $76,650.75 +260.0%N/A1.2 $0.43 9/15/202349,800 shares $19,770.60 +30.7%N/A0.3 $0.40 8/31/202338,100 shares $21,336.00 -75.4%N/A0.2 $0.56 8/15/2023155,100 shares $94,455.90 +15.6%N/A1 $0.61 7/31/2023134,200 shares $84,975.44 +42.6%N/A0.7 $0.63 7/15/202394,100 shares $59,283.00 -20.8%N/A0.5 $0.63 6/30/2023118,800 shares $68,761.44 +611.4%N/A0.4 $0.58 6/15/202316,700 shares $9,853.00 +108.8%N/A0.1 $0.59 5/31/20238,000 shares $5,068.00 -59.4%N/A0 $0.63 5/15/202319,700 shares $12,139.14 +20.9%N/A0.1 $0.62 4/30/202316,300 shares $12,180.99 -30.3%0.1%0.1 $0.75 4/15/202323,400 shares $21,294.00 -14.6%0.1%0.1 $0.91 3/31/202327,400 shares $26,304.00 -26.3%0.1%0.4 $0.96 3/15/202337,200 shares $35,340.00 -13.9%0.1%0.5 $0.95 2/28/202343,200 shares $52,272.00 -30.1%0.2%0.5 $1.21 2/15/202361,800 shares $80,340.00 +56.9%0.2%0.7 $1.30 1/31/202339,400 shares $49,640.06 -49.0%0.1%0.4 $1.26 1/15/202377,200 shares $100,360.00 -34.9%0.3%0.8 $1.30 12/30/2022118,600 shares $125,716.00 +48.3%0.4%1.2 $1.06 12/15/202280,000 shares $110,400.00 -9.7%0.3%0.8 $1.38 11/30/202288,600 shares $127,584.00 +30.3%0.3%0.9 $1.44 11/15/202268,000 shares $64,593.20 +32.0%0.2%0.6 $0.95 10/31/202251,500 shares $51,500.00 -9.8%0.2%0.5 $1.00 10/15/202257,100 shares $57,100.00 -5.3%0.2%0.6 $1.00 9/30/202260,300 shares $63,918.00 -36.4%0.2%0.6 $1.06Most people would never touch this orange powder… would you? (Ad)At first glance, it looks like some ordinary “orange” powder… But in reality, it is a scientific breakthrough in energy technology. One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years. And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out. The question is… Why are the top 1% piling in this much? And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?Well, all the answers you need are right here 9/15/202294,800 shares $134,616.00 -40.0%0.3%1 $1.42 8/31/2022158,100 shares $233,988.00 +59.2%0.6%2 $1.48 8/15/202299,300 shares $178,740.00 +85.6%0.4%2 $1.80 7/31/202253,500 shares $90,415.00 -54.7%0.2%1 $1.69 7/15/2022118,200 shares $195,467.34 +25.5%0.4%2 $1.65 6/30/202294,200 shares $136,590.00 -37.9%0.3%1.4 $1.45 6/15/2022151,600 shares $210,724.00 -39.0%0.5%1.9 $1.39 5/31/2022248,500 shares $372,750.00 +31.0%0.9%2.9 $1.50 5/15/2022189,700 shares $235,228.00 -37.0%0.7%1.9 $1.24 4/30/2022301,000 shares $478,590.00 -28.0%1.1%2.8 $1.59 4/15/2022418,300 shares $836,600.00 +0.6%1.5%3.5 $2.00 3/31/2022415,900 shares $740,302.00 -4.7%1.5%3.4 $1.78 3/15/2022436,400 shares $554,228.00 -9.6%1.6%2.4 $1.27 2/28/2022482,500 shares $670,675.00 +9.2%1.8%2.4 $1.39 2/15/2022441,900 shares $645,174.00 -9.9%1.7%1.8 $1.46 1/31/2022490,200 shares $740,202.00 -7.8%1.8%1.9 $1.51 1/15/2022531,600 shares $909,036.00 +2.0%2.0%1.9 $1.71 12/31/2021521,100 shares $969,246.00 -11.0%1.9%1.8 $1.86 12/15/2021585,400 shares $1.22 million +2.2%2.2%2.3 $2.08 11/30/2021572,600 shares $1.19 million -8.7%2.1%2.4 $2.07 11/15/2021626,800 shares $1.49 million -3.3%2.3%3.2 $2.38 10/29/2021648,000 shares $1.71 million -6.1%2.4%3.5 $2.64 10/15/2021690,400 shares $1.87 million +3.6%2.6%4 $2.71 9/30/2021666,700 shares $2.00 million -6.3%2.5%3.8 $3.00 9/15/2021711,400 shares $2.07 million -5.6%2.7%3.7 $2.91 8/31/2021753,900 shares $2.32 million +5.4%2.8%3.5 $3.08 8/13/2021715,200 shares $2.12 million -7.3%2.7%2.9 $2.97 7/30/2021771,800 shares $2.41 million -18.8%2.9%2.9 $3.12 7/15/2021949,900 shares $3.25 million -1.0%3.6%3.3 $3.42 6/30/2021959,300 shares $3.52 million +17.8%3.6%1.7 $3.67 6/15/2021814,600 shares $3.08 million -13.8%3.1%0.7 $3.78 5/28/2021944,700 shares $3.50 million -14.9%3.5%0.8 $3.70 5/14/20211,110,000 shares $3.63 million -4.3%4.2%0.9 $3.27 4/30/20211,160,000 shares $4.21 million +26.7%4.4%0.7 $3.63 4/15/2021915,500 shares $3.38 million +78.0%3.4%0.3 $3.69 3/31/2021514,200 shares $2.19 million +70.9%1.9%0.2 $4.25 3/15/2021300,800 shares $1.34 million -50.1%1.1%0.1 $4.44 2/26/2021602,500 shares $2.62 million +44.7%2.6%0.3 $4.35 2/12/2021416,500 shares $2.23 million -84.9%1.8%0.2 $5.36 1/29/20212,760,000 shares $16.06 million +8.2%12.6%1.4 $5.82 1/15/20212,550,000 shares $15.45 million +4.9%N/A1 $6.06 12/31/20202,430,000 shares $12.17 million +4.7%N/A1.2 $5.01 12/15/20202,320,000 shares $10.75 million -0.4%N/A1.6 $4.63 11/30/20202,330,000 shares $10.82 million -7.2%N/A1.7 $4.64 11/15/20202,510,000 shares $11.58 million -3.5%N/A5 $4.61 10/30/20202,600,000 shares $11.23 million -11.3%N/A4.9 $4.32 10/15/20202,930,000 shares $14.29 million -5.5%N/A4.1 $4.88 9/30/20203,100,000 shares $15.12 million +2.0%N/A1 $4.88 9/15/20203,040,000 shares $14.85 million -10.3%N/A1 $4.88 8/31/20203,390,000 shares $17.83 million -7.6%N/A1.1 $5.26The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. 8/14/20203,670,000 shares $21.58 million -5.4%N/A1.1 $5.88 7/31/20203,880,000 shares $26.77 million +19.0%N/A1.2 $6.90 7/15/20203,260,000 shares $20.93 million -11.7%N/A1 $6.42 6/30/20203,690,000 shares $21.43 million -13.2%N/A0.7 $5.81 6/15/20204,250,000 shares $28.56 million -3.2%N/A0.8 $6.72 5/29/20204,390,000 shares $28.71 million +8.7%N/A0.7 $6.54 5/15/20204,040,000 shares $25.94 million -28.2%N/A0.7 $6.42 4/30/20205,630,000 shares $36.82 million +10.8%N/A1 $6.54 4/15/20205,080,000 shares $38.40 million +213.6%N/A0.9 $7.56 3/31/20201,620,000 shares $1.85 million +202.9%N/A0.4 $1.14 3/13/2020534,900 shares $604,437.00 -27.4%1.4%1.5 $1.13 2/28/2020736,300 shares $404,965.00 -35.4%1.9%1.1 $0.55 2/14/20201,140,000 shares $649,800.00 -16.8%2.9%1.8 $0.57 1/31/20201,370,000 shares $945,300.00 -4.2%3.5%2.5 $0.69 1/15/20201,430,000 shares $1.07 million -20.1%3.7%6.1 $0.75 12/31/20191,790,000 shares $1.68 million -6.3%4.6%7.8 $0.94 MBRX Short Interest - Frequently Asked Questions What is Moleculin Biotech's current short interest? Short interest is the volume of Moleculin Biotech shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 34,200 shares of MBRX short. 1.53% of Moleculin Biotech's shares are currently sold short. Learn More on Moleculin Biotech's current short interest. What is a good short interest ratio for Moleculin Biotech? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MBRX shares currently have a short interest ratio of 1.0. Learn More on Moleculin Biotech's short interest ratio. What is a good short interest percentage for Moleculin Biotech? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.53% of Moleculin Biotech's floating shares are currently sold short. Is Moleculin Biotech's short interest increasing or decreasing? Moleculin Biotech saw a increase in short interest in May. As of May 15th, there was short interest totaling 34,200 shares, an increase of 10.0% from the previous total of 31,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Moleculin Biotech's float size? Moleculin Biotech currently has issued a total of 2,310,000 shares. Some of Moleculin Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Moleculin Biotech currently has a public float of 2,230,000 shares. How does Moleculin Biotech's short interest compare to its competitors? 1.53% of Moleculin Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Moleculin Biotech: Vaccinex, Inc. (1.71%), Reviva Pharmaceuticals Holdings, Inc. (6.38%), Clene Inc. (0.16%), Xilio Therapeutics, Inc. (2.02%), Immuneering Co. (16.80%), Eyenovia, Inc. (10.27%), HCW Biologics Inc. (0.01%), Acurx Pharmaceuticals, Inc. (4.43%), Lipocine Inc. (3.10%), NRx Pharmaceuticals, Inc. (7.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Moleculin Biotech stock? Short selling MBRX is an investing strategy that aims to generate trading profit from Moleculin Biotech as its price is falling. MBRX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Moleculin Biotech? A short squeeze for Moleculin Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MBRX, which in turn drives the price of the stock up even further. How often is Moleculin Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MBRX, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Vaccinex Short Squeeze Reviva Pharmaceuticals Short Squeeze Clene Short Squeeze Xilio Therapeutics Short Squeeze Immuneering Short Squeeze Eyenovia Short Squeeze HCW Biologics Short Squeeze Acurx Pharmaceuticals Short Squeeze Lipocine Short Squeeze NRx Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MBRX) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.